Erica Golemis, PhD, Associate Director for System-wide Integration at Fox Chase Cancer Center and Chair of the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University, was named Editor-in-Chief of Cancer and Metastasis Reviews today.
“Cancer and Metastasis Reviews has played a valuable role as a venue for thought leaders in the field of cancer research and is currently in a strong position to expand this role over the next decade,” said Golemis. “It will be a privilege to contribute to the growth of the journal.”
Cancer and Metastasis Reviews highlights some of the most important and interesting developments in biology and treatment of malignant disease. It seeks to provide a forum for review and discussion of challenges in cancer research. Each issue presents contributions on a specific topic, with special emphasis given to topics related to the molecular and cellular biology of cancer metastasis and tumor progression.
As Editor-in-Chief, Golemis will be responsible for identifying, soliciting, and promoting articles highlighting critical advances and impactful research of high value to the scientific community.
Golemis has worked in cancer research for over three decades and is currently the William Wikoff Smith Chair in Cancer Research at Fox Chase. Her research focuses on understanding factors contributing to the basis for aggressive tumor growth and on evaluation of protein-targeted drugs, frequently in collaboration with medical and radiation oncologists. Her lab works to identify genetic features associated with specific patterns of therapeutic responses in head and neck, lung, pancreatic, and colorectal cancers.
Golemis is also Chair of the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine, which includes members of the Fels Cancer Institute for Personalized Medicine. The department’s goal is to perform cutting-edge, multidisciplinary research and provide cancer-focused education that together contribute to the control and cure of cancer.
She believes there is already great strength in cancer research and cancer care in the Temple and Fox Chase Cancer Center systems and that her goal is to foster cross-system interactions to enhance innovation.
Golemis is a Fellow of the American Association for the Advancement of Science as well as a member of the American Association for Cancer Research and the American Society for Cell Biology. She has published over 240 articles and edited four books on topics in cancer and biotechnology.
“I am looking forward to serving as Editor-in-Chief of this impactful journal,” said Golemis. “Its value in highlighting emerging developments in molecular and cellular biology of metastasis cannot be overstated. I am eager to lead such a critical effort.”
***
About the Lewis Katz School of Medicine
Founded in 1901, the Lewis Katz School of Medicine at Temple University attracts students and faculty committed to advancing individual and population health through culturally competent patient care, research, education, and service. The School confers the MD degree; MS and PhD degrees in Biomedical Science; the MA in Urban Bioethics; the MS in Physician Assistant studies; a certificate in Narrative Medicine; a non-degree post-baccalaureate program; several dual degree programs with other Temple University schools; continuing medical education programs; and in partnership with Temple University Hospital, 40 residency and fellowship programs for physicians. The School also manages a robust portfolio of publicly and privately funded transdisciplinary studies aimed at advancing the prevention, diagnosis, and treatment of disease -- with specialized research centers focused on heart disease, cancer, substance use disorder, metabolic disease, and other regional and national health priorities. To learn more about the Lewis Katz School of Medicine, please visit: medicine.temple.edu.
About Fox Chase Cancer Center
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427.
Media Contact:
Fox Chase Cancer Center/Lewis Katz School of Medicine
Amy Merves
215-280-0810
[click-for-email]